Details for Patent: 8,030,333
✉ Email this page to a colleague
Title: | Benzimidazole compound crystal |
Abstract: | A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent. |
Inventor(s): | Fujishima; Akira (Hyogo, JP), Aoki; Isao (Hyogo, JP), Kamiyama; Keiji (Osaka, JP) |
Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
Filing Date: | Apr 30, 2010 |
Application Number: | 12/771,486 |
Claims: | 1. A method of treating or preventing ulcer caused by a nonsteroidal anti-inflammatory agent in a mammal in need thereof which comprises administering to said mammal an effective amount of a crystalline compound of (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-- 1H-benzimidazole or a salt thereof and a pharmaceutically acceptable excipient, carrier or diluent. 2. The method of claim 1, wherein said crystalline compound is (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-- 1H-benzimidazole. 3. The method of claim 2, wherein said crystalline compound has an X-ray powder diffraction analysis pattern with characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom. 4. The method of claim 1, wherein said crystalline compound is (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-- 1H-benzimidazole 1.5 hydrate and has an X-ray powder diffraction analysis pattern with characteristic peaks at interplanar spacings (d) of 13.22, 9.60, 8.87, 8.05, 6.61, 5.92, 5.65, 5.02, 4.49, 3.50 and 3.00 Angstrom. |